Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma.
Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with early-stage disease who are suitable for surgery, the treatment of choice is CRS + HIPEC, whereas in advanced-stage patients, systemic trea...
| Publicado en: | Clinical Medicine Insights: Oncology Vol. 19; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
10/17/2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188898019&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 188898019 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 10/17/2025 vid: 19 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 188898019 188898019 188898019 10.1177/11795549251385075 188898019 ppf: 1 ppct: 10 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma. aug: au: Bayram, Doğan Efil, Safa Can Türk, Serap Kara, Oğuz Sekmek, Serhat Yücel, Şebnem Aktürk Esen, Selin Uçar, Gökhan Bal, Oznur Algin, Efnan Uncu, Doğan affil: Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey sug: subj: Drug Efficacy Evaluation Pemetrexed Therapeutic Use Gemcitabine Therapeutic Use Peritoneal Neoplasms Drug Therapy Mesothelioma, Malignant Drug Therapy Platinum Compounds Therapeutic Use Drug Therapy, Combination Peritoneal Neoplasms Prognosis Mesothelioma, Malignant Prognosis Human Retrospective Design Nonexperimental Studies Record Review Hospitals Turkiye Turkiye Adolescence Adult Middle Age Aged Aged, 80 and Over Male Female Smoking Comorbidity Neoplasm Staging Descriptive Statistics Data Analysis Software Mann-Whitney U Test Chi Square Test Fisher's Exact Test Kaplan-Meier Estimator Cox Proportional Hazards Model Neoplasm Metastasis Comparative Studies Cancer Patients Overall Survival Progression-Free Survival Outpatient Service Adolescent: 13-18 years Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Male Female ab: Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with early-stage disease who are suitable for surgery, the treatment of choice is CRS + HIPEC, whereas in advanced-stage patients, systemic treatments are applied. Pemetrexed plus platinum regimens are at the forefront of first-line systemic treatments. Gemcitabine plus platinum regimens are rarely used as first-line treatment for MPeM. The aim of our study is to compare the efficacy of first-line pemetrexed plus platinum with gemcitabine plus platinum regimens in patients with MPeM. Methods: In this study, a retrospective analysis was conducted on 48 patients with MPeM who were followed up in our clinic between 2001 and 2025. In our study, 28 patients received pemetrexed plus platinum as a first-line regimen, while 20 patients received gemcitabine plus platinum. The median overall survival (OS), median progression-free survival (PFS), and response rates for both regimens were analyzed. In addition, prognostic factors influencing overall survival were investigated in the entire patient population. Results: The median PFS and OS were 11.1 months and 17.0 months for pemetrexed and 8.01 months and 14.4 months for gemcitabine. Although pemetrexed showed numerically higher PFS and OS, the difference was not statistically significant. The objective response rate (ORR) and disease control rate (DCR) were 32.1% and 57.1% for pemetrexed, compared with 25% and 40% for gemcitabine, showing pemetrexed's superiority in response rates. In the entire patient population, CRS + HIPEC was the main prognostic factor for survival. Conclusion: We have demonstrated that the pemetrexed + platinum regimen has better response rates compared with the gemcitabine + platinum regimen in MPeM patients. However, gemcitabine-based regimens can be used as an alternative to pemetrexed in patients with MPeM. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|